Breast angiosarcoma that is not related to radiation exposure: a comprehensive review of the literature.
Breast angiosarcomas that are not related to previous radiotherapy are very rare. Surgical resection is the primary treatment for these tumors, but there is no general agreement on the extent of surgery. The role of multimodality adjuvant treatment also remains controversial. The aim of this study was to summarize the available data from the largest published series of patients in terms of management and outcome. We also sought to identify prognostic factors influencing patient survival. We have included studies presenting detailed data on multimodality therapy and survival of patients with breast angiosarcoma. Ten studies presenting data on 280 patients were included in the review. Seventy-five percent of patients underwent a total mastectomy and 25% had breast-conserving treatment (BCT). In 42% of patients, an axillary node dissection was combined with mastectomy or BCT. Thirty-six percent of patients received chemotherapy and 35% were treated with radiotherapy in an adjuvant or neoadjuvant setting. Survival varied significantly according to tumor size and grade. Adjuvant multimodality therapy may improve the outcome in selected patients with breast angiosarcoma. Tumor size, grade, and margin status are the most important prognostic factors for survival.
Department of Surgery, University of Athens, 71 Kifisias Street, Athens, Greece.
Ioannis G
IG
Kaklamanos
Konstantinos
K
Birbas
Konstantinos N
KN
Syrigos
Dimitrios
D
Vlachodimitropoulos
Nikolaos
N
Goutas
Gerassimos
G
Bonatsos
D001943:Breast Neoplasms / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006394:Hemangiosarcoma / Q000401:mortality / Q000628:therapy*; D006801:Humans; D011379:Prognosis; D016896:Treatment Outcome
Ann Surg Oncol. 2008 Oct;15(10):2739-48
18521685
J Surg Oncol. 2006 Oct 1;94(5):368-74
16967461
J Surg Oncol. 2004 Sep 1;87(3):121-5
15334638
Radiology. 2007 Mar;242(3):725-34
17325063
Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):383-90
10661345
Breast. 2006 Apr;15(2):255-8
16000250
Radiother Oncol. 1999 Aug;52(2):173-8
10577703
Radiother Oncol. 2007 Dec;85(3):355-61
18023492
Cancer. 2007 Jul 1;110(1):173-8
17541936
Am J Clin Oncol. 2007 Oct;30(5):461-5
17921704
Cancer. 2005 Jun 25;105(3):145-51
15844179
Cancer. 1987 Oct 15;60(8):1800-8
3308055
Am J Surg Pathol. 1981 Oct;5(7):629-42
7199829
Am J Surg Pathol. 1983 Jan;7(1):53-60
6402946
Arch Gynecol Obstet. 2002 Nov;267(1):43-5
12410374
J Clin Oncol. 1988 May;6(5):854-62
3367188
Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):969-76
7607971
Am J Surg Pathol. 2008 Dec;32(12):1896-904
18813119
Cancer. 1988 Nov 15;62(10):2145-51
3179927
AJR Am J Roentgenol. 2008 Feb;190(2):533-8
18212243
Cancer. 2008 Aug 1;113(3):573-81
18521899
J Clin Oncol. 1996 May;14(5):1679-89
8622088
J Clin Oncol. 2003 Jul 1;21(13):2583-8
12829679
Br J Cancer. 1995 Aug;72(2):469-75
7640234
Breast Cancer Res Treat. 2007 Sep;105(1):81-5
17115110
Arch Surg. 1995 Feb;130(2):221-3
7848095
J Clin Oncol. 2001 Mar 1;19(5):1238-47
11230464
Surg Clin North Am. 1996 Apr;76(2):383-92
8610270
Am J Surg. 2003 Oct;186(4):359-61
14553850
Eur J Cancer. 2006 Nov;42(16):2715-21
17023158
Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):671-5
8226163
Br J Cancer. 2004 Jul 19;91(2):237-41
15187996
Oncology (Williston Park). 1991 Jun;5(6):105-18; discussion 118, 120, 123-4
1831635
Cancer. 2003 Apr 15;97(8):1832-40
12673708